Trinity Biotech’s Uni-GoldTM HSV-2 Rapid is a single use immunoassay for the qualititative detection of human IgG class antibodies to HSV-2 in human whole blood (venous or capillary) or serum. This product is the newest addition to the Uni-GoldTM range of STD rapid tests. This easy to use test features a 2 step procedure, giving results within 15 minutes. Used as a frontline screening assay, the Uni-GoldTM HSV-2 Rapid complements the company’s confirmatory CaptiaTM HSV Type Specific ELISA assays. The Uni-GoldTM HSV-2 Rapid will ensure communities and STD clinics can detect HSV-2 faster and more accurately at Point-Of-Impact. The HSV-2 test now joins Trinity’s established HIV test as part of the Uni-GoldTM brand of Point-Of-Impact rapid tests.
Read more

REMISOL Advance* data management system from Beckman Coulter is a unique software product that consolidates patient test information from multiple instruments in the lab. REMISOL Advance is also able to manage multiple labs in the hospital network utilizing a single server. It streamlines laboratory workflow as well as the result-management process, offering an optional Extended Quality Control (EQC) module, enhancing the laboratory quality control process even further.

REMISOL Advance optimizes lab operations by helping decrease turnaround times for results reporting, standardizing laboratory processes and enabling the connectivity of multiple instruments through a single point of management. REMISOL Advance, in unison with EQC, provides an integrated view of the analyzers’ QC status with patient results to make confident decisions on releasing patient results. Audit and traceability features allow all events related to the creation, modification or deletion of a result to be saved for later reference.

*_{^{REMISOL Advance is a trademark of Normand-Info SAS.}}

Read more

Nail infections are caused by dermatophytes, most commonly by Trichophyton rubrum, followed by Trichophyton mentagrophytes. As onychomycosis requires long-term systemic antifungal treatment, the correct identification of causal fungi is mandatory. The time required for traditional species identification by culture ranges from two to four weeks. With SSI™ Dermatophyte PCR Kit dermatophytes, and T. rubrum specifically, can be detected within five hours. Also, a study has showed that this multiplex PCR method increases the detection of pan-dermatophytes by 4.3% and T.rubrum by 18.6% compared with conventional methods (Brillowska-Dabrowska A, et al. Jour Clin Microbiol 2007; 1200). Hence SSI® Dermatophyte PCR Kit is a time- and cost-effective alternative. SSI® Dermatophyte PCR Kit is CE-marked. It contains all reagents and controls needed to perform a multiplex PCR detection of dermatophytes causing fungal infections in nails. It comes in boxes with material for 100 tests.
Read more

The finding that rheumatoid arthritis (RA) patients often produce antibodies against citrullinated peptides and proteins was a major advance both in understanding the mechanisms that trigger the disease and in its early diagnosis. Citrulline is a “nonstandard” amino acid that forms in the inflammatory environment as a result of the action of the enzyme peptidiliargininine deaminase on arginine residues present in proteins. Anti-citrullinated peptides are produced locally in the synovium of RA patients. The introduction of new immunoassays based on specially selected cyclic citrullinated peptides (CCP), allowed the development of tests with sensitivity equal to or better than traditional rheumatoid factor (RF), but with a much higher specificity. In addition to this, it was demonstrated that the presence of anti-CCP is both an early marker of AR (anti-CCP can be found up to 10 years before the onset of symptoms) and a marker of the severity of the disease. DIESSE is offering the new second generation anti-CCP Chorus kit to complete its line of tests for the serological diagnosis of systemic inflammatory diseases, in the convenient and pratical single determination format.
Read more

The Early Embryo Viability Assessment (Eeva) test is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. Eeva uses intelligent computer vision software to measure key scientifically and clinically validated cell-division parameters from video images. It predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage, a critical milestone in embryo development. Until now, the field of reproductive medicine has been using subjective observation to determine embryo viability. With the commercial launch of Eeva, IVF clinics and their patients will now have access to a noninvasive test that delivers consistent, objective and actionable information to help identify viable embryos and determine which ones offer the greatest potential for transfer. The safety and efficacy of Eeva were validated in a prospective, multi-centre, 160-patient clinical trial, results of which were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey. In the study, Eeva was able to predict blastocyst formation at the cleavage stage with 85% specificity, reducing the false positive rate from 43% to 15% compared with traditional morphology selection. Eeva also demonstrated the ability to track and analyse cell division timings with greater than 90% accuracy. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Eeva provides early results that allow for timely decision-making. During the IVF cycle, there is a checkpoint on Day 3 in which clinicians make decisions about whether to transfer embryos. Eeva provides information about embryo viability as early as Day 3, allowing clinicians to select a viable embryo in a timely manner, thereby increasing the likelihood of a successful patient outcome. Eeva consists of the Eeva Dish, which contains microwells enabling the tracking of the individual development of each embryo and allowing embryos to grow under group culture technique; the Eeva Scope that fits into most standard IVF incubators and provides automatic dark-field image capture and cell-division tracking without intervention by the embryologist or excessive light exposure to the embryos; the Eeva Scope Screen that fits on the outside of the incubator and allows the embryologist to control each patient session and view the latest images without opening the incubator or disturbing the embryos; the Eeva Station where images and videos for each Eeva patient session can be easily reviewed. The downloadable reports and videos may aid when counseling patients and improve the overall patient experience. Eeva is currently approved and available for use in the EU with the first installation at the Hewitt Fertility Centre in Liverpool.  

Read more